Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 4,285 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $25.00, for a total transaction of $107,125.00. Following the transaction, the director directly owned 25,107 shares in the company, valued at approximately $627,675. The trade was a 14.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Enliven Therapeutics Stock Down 3.7%
ELVN stock opened at $25.03 on Tuesday. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $29.98. The firm has a 50-day simple moving average of $19.17 and a 200-day simple moving average of $19.97. The stock has a market capitalization of $1.49 billion, a P/E ratio of -13.60 and a beta of 0.41.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Enliven Therapeutics News Summary
Here are the key news stories impacting Enliven Therapeutics this week:
- Positive Sentiment: MSN published a piece noting Enliven has rising relative price strength, a technical signal that can attract momentum traders and institutional interest. Article Title
- Neutral Sentiment: Short-interest data reported an anomalous reading (zero shares reported as of Jan 12), producing no clear bearish signal; the metric is effectively neutral/uncertain and unlikely to explain today’s move on its own.
- Negative Sentiment: Chief insider selling: CEO/insider Joseph P. Lyssikatos completed multiple sales (41,302 shares at ~$24.05 and 91,198 shares at ~$27.22), generating roughly $3.47M in proceeds and reducing his stake by double-digit percentages in those transactions — a notable supply event that can pressure the share price. SEC Filing
- Negative Sentiment: Director sales: Richard A. Heyman sold 9,635 shares (avg $25.03) and 4,285 shares (avg $25.00) across Jan 8–9, totaling ~13,920 shares and ≈$348k — further insider selling that likely added downward pressure. SEC Filing
Wall Street Analyst Weigh In
ELVN has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.
View Our Latest Report on Enliven Therapeutics
Hedge Funds Weigh In On Enliven Therapeutics
Several large investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after buying an additional 930 shares during the period. Quantbot Technologies LP grew its position in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Enliven Therapeutics during the third quarter worth about $96,000. Tower Research Capital LLC TRC boosted its stake in shares of Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock valued at $106,000 after purchasing an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS grew its holdings in shares of Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock valued at $136,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
